PTC Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>PTC Therapeutics, Inc. has filed its 2023 10-K annual report detailing financial performance and corporate information.</b>

AI Summary

PTC THERAPEUTICS, INC. (PTCT) filed a Annual Report (10-K) with the SEC on February 29, 2024. PTC Therapeutics, Inc. filed its 2023 Annual Report on Form 10-K on February 29, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is 100 Corporate Court, South Plainfield, NJ 07080-2449. PTC Therapeutics, Inc. is classified under Standard Industrial Classification code 2834 (Pharmaceutical Preparations). The filing includes financial data for the fiscal years 2020 through 2023, detailing common stock, retained earnings, and paid-in capital.

Why It Matters

For investors and stakeholders tracking PTC THERAPEUTICS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of PTC Therapeutics' financial health and operational status for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial statements and disclosures within the report are essential for understanding the company's revenue, expenses, assets, liabilities, and equity, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — PTC THERAPEUTICS, INC. shows moderate risk based on this filing. The company's financial performance and future outlook are subject to the inherent risks and uncertainties of the pharmaceutical industry, including drug development success, regulatory approvals, and market competition, as detailed in their 10-K filings.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand PTC Therapeutics' financial position and strategic direction.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-02-29 — Filing Date (Date filed)
• 75708889 — Value (2023 Financial Data)
• 73104692 — Value (2022 Financial Data)

Key Players & Entities

• PTC THERAPEUTICS, INC. (company) — Filer name
• 2023 (date) — Fiscal year end
• 2024-02-29 (date) — Filing date
• 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ 07080-2449 (address) — Business and mailing address
• 2834 (industry) — Standard Industrial Classification
• PHARMACEUTICAL PREPARATIONS (industry) — Standard Industrial Classification description
• 001-35969 (filing_id) — SEC File Number

FAQ

Industry Context

PTC Therapeutics operates within the pharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases.

Regulatory Implications

As a pharmaceutical company, PTC Therapeutics is subject to stringent regulatory oversight from bodies like the FDA regarding drug development, approval, and marketing.

What Investors Should Do

1. Analyze the detailed financial statements for revenue, net income, and cash flow.
2. Review the risk factors section for potential challenges and uncertainties.
3. Assess the company's strategic initiatives and outlook for future growth.

Key Dates

• 2023-12-31: Fiscal Year End — Covers the financial performance for the year.
• 2024-02-29: Filing Date — Official submission date of the 10-K report.

Year-Over-Year Comparison

This filing represents the company's comprehensive annual update for the fiscal year 2023, following previous filings which would have covered prior periods.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo

Filing Documents

• tmb-20231231x10k.htm (10-K) — 4209KB
• tmb-20231231xex10d48.htm (EX-10.48) — 399KB
• tmb-20231231xex23d1.htm (EX-23.1) — 9KB
• tmb-20231231xex31d1.htm (EX-31.1) — 12KB
• tmb-20231231xex31d2.htm (EX-31.2) — 14KB
• tmb-20231231xex32d1.htm (EX-32.1) — 7KB
• tmb-20231231xex32d2.htm (EX-32.2) — 7KB
• tmb-20231231xex97d1.htm (EX-97.1) — 49KB
• tmb-20231231x10k006.jpg (GRAPHIC) — 46KB
• tmb-20231231xex97d1001.jpg (GRAPHIC) — 4KB
• 0001558370-24-002196.txt (&nbsp;) — 18220KB
• tmb-20231231.xsd (EX-101.SCH) — 102KB
• tmb-20231231_cal.xml (EX-101.CAL) — 107KB
• tmb-20231231_def.xml (EX-101.DEF) — 476KB
• tmb-20231231_lab.xml (EX-101.LAB) — 974KB
• tmb-20231231_pre.xml (EX-101.PRE) — 768KB
• tmb-20231231x10k_htm.xml (XML) — 3439KB

Business

Item 1. Business 6

Risk Factors

Item 1A. Risk Factors 61

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 111

Cybersecurity

Item 1C. Cybersecurity 111

Properties

Item 2. Properties 112

Legal Proceedings

Item 3. Legal Proceedings 113

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 113 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities 114

[Reserved]

Item 6. [Reserved] 114

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 114

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 136

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 138

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 197

Controls and Procedures

Item 9A. Controls and Procedures 197

Other Information

Item 9B. Other Information 200

Disclosures Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosures Regarding Foreign Jurisdictions that Prevent Inspections 200 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 202

Executive Compensation

Item 11. Executive Compensation 202

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 202

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 202

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 202 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 203

Form 10-K Summary

Item 16. Form 10-K Summary 209

SIGNATURES

SIGNATURES 210 i Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our products or product candidates that we commercialize or may commercialize in the future; our expectations with respect to the European Commission's potential adoption of the Committee for Medicinal Products for Human Use's negative opinion for the renewal of the conditional marketing authorization for Translarna TM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in the European Economic Area, or EEA, following a re-examination procedure and our ability to maintain such conditional marketing authorization or identify other potential mechanisms in which we may provide Translarna to nmDMD patients in the EEA ; our ability to maintain our marketing authorizations in other jurisdictions in which Translarna has been approved; our ability to utilize results from Study 041 and from our international drug registry study to support a marketing approval for Translarna for t

Business

Item 1. Business Overview We are a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Our ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. Our mission is to provide access to best-in-class treatments for patients who have little to no treatment options. Our strategy is to leverage our strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. We believe that this allows us to maximize value for all of our stakeholders. Our Pipeline We have a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The chart and the disclosure directly below summarizes the status of our significant clinical-stage programs and commercial products as of the date of this report, including those with our strategic partners: Global Commercial Footprint o Global DMD Franchise – We have two products, Translarna TM (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna currently has conditional marketing authorization in the European Economic Area, or EEA, for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged two years and older. On January 25, 2024, the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, issued a negative opinion for the conditional marketing authorization following a re-examination procedure. In accordance

View Full Filing

View this 10-K filing on SEC EDGAR